ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 2025 Jefferies Global Healthcare Conference, being held June 3-5, 2025.
Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference.
About ARTHEx Biotech ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
For more information, please visitwww.arthexbiotech.com and engage with us on LinkedIn.
https://mma.prnewswire.com/media/2068054/ARTHEx_Biotech_Logo.jpg
https://c212.net/c/img/favicon.png?sn=LA98416&sd=2025-05-29
View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-to-participate-in-the-2025-jefferies-global-healthcare-conference-302467883.html
SOURCE ARTHEx Biotech
https://rt.newswire.ca/rt.gif?NewsItemId=LA98416&Transmission_Id=202505290300PR_NEWS_USPR_____LA98416&DateId=20250529